Bright Green Corp BGXX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BGXX is a good fit for your portfolio.
News
-
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
-
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
-
Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.
-
BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS
-
BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS
Trading Information
- Previous Close Price
- $0.18
- Day Range
- $0.18–0.20
- 52-Week Range
- $0.15–1.81
- Bid/Ask
- $0.19 / $0.22
- Market Cap
- $37.96 Mil
- Volume/Avg
- 164,856 / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- —
- Total Number of Employees
- 5
- Website
- https://www.brightgreen.us
Comparables
Valuation
|
Metric
|
BGXX
|
SCLX
|
ANIP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 13.76 |
Price/Book Value | 3.36 | — | 3.07 |
Price/Sales | — | 2.45 | 2.43 |
Price/Cash Flow | — | — | 12.56 |
Price/Earnings
BGXX
SCLX
ANIP
Financial Strength
|
Metric
|
BGXX
|
SCLX
|
ANIP
|
|---|---|---|---|
Quick Ratio | 0.00 | 0.15 | 2.63 |
Current Ratio | 0.04 | 0.19 | 3.57 |
Interest Coverage | — | −106.04 | 1.74 |
Quick Ratio
BGXX
SCLX
ANIP
Profitability
|
Metric
|
BGXX
|
SCLX
|
ANIP
|
|---|---|---|---|
Return on Assets (Normalized) | −36.66% | −106.47% | 10.25% |
Return on Equity (Normalized) | −65.85% | — | 22.54% |
Return on Invested Capital (Normalized) | −50.30% | −1,960.39% | 16.08% |
Return on Assets
BGXX
SCLX
ANIP
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Cdhtjsfvb | Wly | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Wvvqhpbyn | Myzwbl | $70.8 Bil | |
HLN
| Haleon PLC ADR | Pnfppcjsw | Cgm | $38.2 Bil | |
VTRS
| Viatris Inc | Fvxxjxvf | Hzns | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Nkwghmjf | Nqwl | $12.5 Bil | |
CTLT
| Catalent Inc | Ybtnzrgl | Lnjbcj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Xqhvbhds | Hdqkw | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Tpcyxqgzk | Jkpg | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ckhvmvbp | Ndktd | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Wgmvmlvgdf | Lmkj | $2.9 Bil |